Sanofi-A Ventis Deutschland Gmbh

Sanofi

Genzyme Corporation

Sanofi-Aventis

Aventis Pharma Deutschland, Gmbh

Hans-Peter Nestler

Otmar Klingler

Manfred Schudok

Herman Schreuder

Hauke Szillat

Hans Matter

Martin Lorenz

Volkmar Wehner

Elisabeth Defossa

Markus Follmann

Uwe Heinelt

Kurt Ritter

Reinhard Kirsch

Holger Heitsch

Anthony C Scotese

Kent W Neuenschwander

Henning Steinhagen

Andreas Lindenschmidt

Maria Mendez-Perez

Christopher Kallus

Nils Rackelmann

Sven Grueneberg

Gernot Zech

Thomas Leeuw

The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.

Isoxazolidines as RIPK1 inhibitors and use thereof

The present disclosure relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals

The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.

Imidazole derivatives used as TAFIa inhibitors

The present invention relates to compounds of formula I, The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Malonamide derivatives with antithrombotic activity

Urea derivatives with antiproteolytic activity

Growing community of inventors

Frankfurt-am-Main, Germany

Hauke Szillat